Billerica, Mass.-based Quanterix is selling 2,651,108 shares of its common stock and expects to collect gross proceeds of approximately $84.8 million. Quanterix also granted underwriters a 30-day option to purchase up to 397,666 additional shares at the public offering price.
The digital biomarker analysis technology developer expects the offering to close on Aug. 11, 2020, subject to customary closing conditions, according to a news release. SVB Leerink and Cowen are acting as joint bookrunning managers for the offering. Canaccord Genuity is acting as co-manager for the offering.
Quanterix did not reveal its intended use of proceeds. Currently, its Simoa digital health solution is used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.